PTX Prescient Therapeutics Limited
—Mkt Cap: —P/E: —1d ago
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy …
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value38.23M USD
Revenue (TTM)2.39M USD
Gross Profit2.39M USD
Net Income (TTM)-4.84M USD
Revenue/Share0.0030 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000PTX3
Valuation
P/E (Trailing)—
P/E (Forward)6.10
PEG—
EV/EBITDA-7.87
EV/Revenue16.03
P/S20.22
P/B4.36
EPS (TTM)-0.01
EPS (Forward)0.01
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-137.67%
EBITDA Margin-203.69%
Profit Margin-202.91%
ROE-49.31%
ROA-43.01%
Growth
Revenue Growth-26.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.99M USD
CapEx (TTM)—
FCF Margin-116.12%
FCF Yield—
Net Debt-6.10M USD
Net Debt/EBITDA1.26
Balance Sheet
Debt/Equity0.02
Current Ratio7.14
Quick Ratio6.49
Book Value/Sh0.01 AUD
Cash/Share0.0090 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateDec 2, 2014
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.14B
Float893.63M
Insiders12.77%
Institutions0.77%
Technical
SMA 500.0702 AUD
SMA 2000.0683 AUD
Beta0.85
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)558.92K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—